en · de · es · fr · pt
melanotan-2-notes.peptides6908.com › Faq › Chemical Background And Receptor Activity — Field Notes

Chemical Background And Receptor Activity — Field Notes

By Editorial Desk · published 2026-03-07 · last reviewed 2026-04-19 · Faq

This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.

Chemical Background and Receptor Activity

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAlpha-MSH analogue with a lactam ring
Molecular formulaC50H69N15O9Commonly cited value for the neutral peptide
Molecular weight1024.18 g/molCalculated for the free molecule
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water, DMSO and ethanolDissolution in pure water is often slow

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Related pages on this site

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Notes from published material

Analysis of X chromosome STRs by Perera et al. (2021) found the Sinhalese (as well as Sri Lankan Tamils and Sri Lankan Muslims) clustered close to the Bangladeshis, apart from the Indian Bhil tribe, other Indians and Europeans reflecting a shared Indo-Aryan ancestry rather than to the Indian Tamils of Sri Lanka. Genetic distance analysis by Kirk (1976) found the Sinhalese to be closer to the Bengal than they are to populations in Gujarat or the Panjab. D1S80 allele frequency (a popular allele for genetic fingerprinting) is also similar between the Sinhalese and Bengalis, suggesting the two groups are closely related.

== Products == Its primary products are based on Morpholino oligomers (PMOs), synthetic nucleic acid analogs that were conceived of by James Summerton and invented by Summerton with Dwight Weller, originally developed under the name NeuGene Antisense. Since morpholino oligomers can form sequence-specific double-stranded complexes with RNA they are suitable use in antisense therapy. In one application, translation blocking, a morpholino oligomer binds to messenger RNA produced by a known disease-causing gene to prevent it from being translated into protein. Morpholinos can also work as splice-switching oligos, targeting pre-mRNA to alter splicing and so causing changes in the structure of the mature mRNA (the mechanism of the approved drug eteplirsen). Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, treatment of some mutations causing Duchenne muscular dystrophy (DMD), and inhibition of infectious diseases. Their greatest clinical and commercial success thus far has been in the treatment of DMD. A new class of Morpholino oligos, the peptide-linked Morpholinos or PPMO, are linked to an arginine-rich cell-penetrating peptide to enhance their delivery into cells and have entered clinical trials.

Papers of Gene Adams (museum educator) Papers of Marina Foster (ILEA teacher and activist) Papers of Brenda Francis (ILEA teacher) Papers of Trevor Jaggar (educator and ILEA schools inspector) Papers of Martin Lightfoot (director of Penguin Education and education textbook reformer) Papers of David Medd and Mary Medd (educational architects) Papers of Professor Kate Myers (education academic who undertook research for ILEA) Papers of Cynthia Reynolds (ILEA teacher) Photographic Archive of the Architects and Building Branch, Ministry of Education Records of the ALPAG (All London Parents Action Group) and Parents Initiative (campaigning organisations) Records of the Records of the ILEA Bridging Course (officially known as the ILEA/EEC Transition from School to Work Project) Records of the London Parents' Ballot Campaign (which campaigned to stop the closure of ILEA) The Institute of Education also holds a library of books and publications which was transferred from the ILEA Learning Resources Branch following its closure in 1990.

== See also == Iran and weapons of mass destruction Catholic peace traditions Christian pacifism Christianity and violence Just war theory Peace churches Reactions to the 2026 Iran war Regime change efforts in the 2026 Iran war Analysis of the 2026 Iran war Use of religious language and symbolism in the Gaza war

Sources: en.wikipedia.org

Further detail

{\displaystyle {\begin{aligned}{\cfrac {V_{\max }}{1+{\cfrac {\ce {[I]}}{K_{i}}}}}&={V_{\max }}\left({\cfrac {K_{i}}{K_{i}+[{\ce {I}}]}}\right)&&{\text{multiply by }}{\cfrac {K_{i}}{K_{i}}}=1\\&={V_{\max }}\left({\cfrac {K_{i}+[{\ce {I}}]-[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{add }}[{\ce {I}}]-[{\ce {I}}]=0{\text{ to numerator}}\\&={V_{\max }}\left(1-{\cfrac {[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{simplify }}{\cfrac {K_{i}+[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}=1\\&=V_{\max }-V_{\max }{\cfrac {\ce {[I]}}{K_{i}+[{\ce {I}}]}}&&{\text{multiply out by }}V_{\max }\end{aligned}}}

== External links == "Opioid Receptors: μ". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. mu+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human OPRM1 genome location and OPRM1 gene details page in the UCSC Genome Browser.

=== 11 April === Denmark's Acting Defence Minister, Troels Lund Poulsen, stated that Denmark will provide Ukraine with Leopard 1A5 tanks before summer, and hopes to provide as many as 100 within six months. The Russian State Duma passed legislation to change the nature of conscription summons and how they were served. Previously a summons had to be physically served on the person being called up. Now a summons is deemed to be served once it appears on the government services portal called "Gosuslugi". Failure to obey such a summons could mean potential "bans on driving, registering a company, working as a self-employed individual, obtaining credit or loans, selling apartments, buying property or securing social benefits."

Autolytic debridement is the use of moist dressings to promote autolysis with the body's own enzymes and white blood cells. This is a slow process, but mostly painless, and is most effective in individuals with a properly functioning immune system. Biological debridement, or maggot debridement therapy, is the use of medical maggots to feed on necrotic tissue and therefore clean the wound of excess bacteria. Although this fell out of favor for many years, in January 2004, the FDA approved maggots as a live medical device. Chemical debridement, or enzymatic debridement, is the use of prescribed enzymes that promote the removal of necrotic tissue. Mechanical debridement is the use of debriding dressings, whirlpool or ultrasound for slough in a stable wound. Surgical debridement, or sharp debridement, is the fastest method, as it allows a surgeon to quickly remove dead tissue.

Similarly, in the North Korean context, "Arduous March" does not directly refer to economic hardship, but a firm resolve to carry out tasks of the party. In June 2021, Kim Jong Un called a meeting to sack several officials over a "severe" COVID-19 breach and warned of a great crisis caused by the pandemic in the country. Despite this, the recently demoted Pak Jong-chon was promoted up to secretary of the Party Central Committee, and rejoined the Politburo as a full member. American activist Tim A. Peters said that there were signs of "enormous stress on the North Korean population" due to the pandemic and associated restrictions, and that he suspected COVID-19 was spreading within the country despite the lack of confirmed cases. In July 2021, North Korea rejected shipments of around two million doses of the Oxford-AstraZeneca vaccine, citing concerns over potential side effects. The same month, Russia also offered to supply the country with its own Sputnik V vaccine on multiple occasions. In September 2021, the country rejected three million doses of the Chinese CoronaVac vaccine which were offered to it under the COVAX programme, asking that the doses be reallocated to other nations. On 27 August, the WHO reported that 37,291 people with flu-like symptoms had so far been tested for COVID-19 in the country, with all testing negative. In October 2021, it was reported by NK News that money coupons were becoming widespread in North Korea, due to COVID-19 controls reportedly causing cash printing issues.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Is melanotan-2 an approved medicine?

No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.

Why does melanotan-2 attract research interest?

Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Network